KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Acquisitions & Divestments (2016 - 2025)

Teva Pharmaceutical Industries filings provide 13 years of Change in Acquisitions & Divestments readings, the most recent being $42.0 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments changed N/A to $42.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $82.0 million, a 105.0% increase, with the full-year FY2025 number at $42.0 million, up 5.0% from a year prior.
  • Change in Acquisitions & Divestments hit $42.0 million in Q4 2025 for Teva Pharmaceutical Industries, up from $40.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $107.0 million in Q2 2021 to a low of $1.0 million in Q3 2022.
  • Median Change in Acquisitions & Divestments over the past 4 years was $40.0 million (2024), compared with a mean of $36.9 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: soared 3466.67% in 2021 and later tumbled 97.2% in 2022.
  • Teva Pharmaceutical Industries' Change in Acquisitions & Divestments stood at $19.0 million in 2021, then plummeted by 94.74% to $1.0 million in 2022, then surged by 3900.0% to $40.0 million in 2024, then rose by 5.0% to $42.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $42.0 million (Q4 2025), $40.0 million (Q3 2024), and $1.0 million (Q3 2022) per Business Quant data.